Nabriva Therapeutics and Roivant Sciences, have launched a collaboration to develop and commercialize lefamulin in greater China.    Lefamulin has completed a pivotal, international Phase 3 clinical trial for the treatment of adults with moderate to severe community-acquired bacterial pneumonia (CABP). Topline data from a second pivotal, international Phase 3 clinical trial are expected in the spring of 2018.   Under the license agreement, Nabriva has granted a Roivant subsidiary a...